SOD1 and amyotrophic lateral sclerosis: Our results highlight a complex, time‐dependent differential response of CSF biomarkers to tofersen treatment, and may pave the way for developing a panel of responsive proteins to make biomarker endpoints more robust in clinical trials for SOD1‐ALS and beyond.